Representative image showing blood pressure monitoring machine
Credit: iStock Photo
Bengaluru: Japanese medical device-maker Omron is setting up its first facility in Chennai to manufacture blood pressure monitoring machines (BPM). The company expects the production to commence by December this year.
Currently, the company is importing BPMs from its Vietnam facility for sale in India. The exact capacity will be determined once the production starts and depending on the demand, said Hiroshi Ogawa, Managing Director, Omron Healthcare India Pvt Ltd.
"There are about 200 million people in India suffering from hypertension and the condition requires daily monitoring. So, the patients need to have a home monitoring device. Our aim is to provide an affordable BPM to patients in India," Ogawa told DH.
Omron on Thursday launched KeeboHealth, an AI-powered connected health platform for remote cardiac care in collaboration with Bengaluru-based Tricog Health, an AI-driven cardiac care company.
Ogawa said Omron enjoys almost 50 per cent market share in the medical devices market in India with a range of products and services for cardiovascular condition management, remote patient monitoring, respiratory care, and pain therapy devices. To begin with, the company aims to manufacture about 1 million blood pressure monitoring devices at its Chennai facility and ramp it up gradually, he said.
Dr Charit Bhograj, CEO & Founder of Tricog Health, said an average 3 million people lose their lives every year due to cardiac diseases and about 30 million people are suffering from blood pressure. The company aims to address this issue by enabling the patients to monitor their BP at home with the help of their product. The company has also partnered with six state governments in India to enable easy access to healthcare for the people suffering from blood pressure and cardiovascular diseases.
"By continuously analysing patient data and detecting early warning signs, we can deliver timely, tailored interventions, even in regions where access to specialists is limited," Dr Bhograj said.